NCT02303977

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see how well the combination of Abraxane and gemcitabine works in people with advanced adenocarcinoma NSCLC who have already had treatment for their disease. Gemcitabine and Abraxane are FDA approved chemotherapies; however, the FDA has not approved this combination in the treatment of this specific type of cancer. Patients may continue to receive the study drugs until their disease gets worse or they have unacceptable side effects.

Conditions

• Patients With Stage IV or Recurrent Adenocarcinoma of the Lung

Interventions

Type	Name	Description
DRUG	Abraxane
DRUG	Gemcitabine

Timeline

• Start date: 2015-06-26
• Primary completion: 2020-04-30
• Completion: 2020-04-30
• First posted: 2014-12-01
• Last updated: 2021-09-29
• Results posted: 2021-09-29